 six-year mortality from stroke in 350,977 men
screened for the multiple risk factor intervention trial. N Engl J Med
1989;320:904-10.
80. Bots ML, Elwood PC, Nikitin Y, Salonen JT, Freire de
Concalves A, Inzitari D, et al. Total and HDL cholesterol and risk
of stroke. EUROSTROKE: a collaborative study among research
centres
in
Europe.
J
Epidemiol
Community
Health
2002;56(Suppl 1):i19-24.
81. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke
mortality in the Women’s Pooling Project. Stroke 2002;33:1863-8.
82. Bucher HC, Grifﬁth LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Ann Intern Med 1998;128:89-95.
83. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C,
et al. Efﬁcacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14
randomised trials of statins. Lancet 2005;366:1267-78.
84. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB,
Hennerici M, Rudolph AE, et al. High-dose atorvastatin after
stroke or transient ischemic attack. N Engl J Med 2006;355:
549-59.

85. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE,
Callahan A 3rd, et al. Effects of intense low-density lipoprotein
cholesterol reduction in patients with stroke or transient ischemic
attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007;38: